SCNI Scinai Immunotherapeutics Ltd.

CIK 0001611747 4 ready 8-Ks latest June 8, 2023, 7:59 PM ET RSS · JSON

Ready 8-Ks 4

Latest filing June 8, 2023, 7:59 PM ET

Top materiality 0.60

Event mix other_material ×2 · leadership ×1 · regulatory ×1

Sentiment 0 pos · 1 neg · 3 neu

Executive change recent →

Recent 8-K filings for SCNI

Highest-materiality recent filing

BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG

June 8, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 ◈ Material Agreements

Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.
Within 45 days of June 4, 2023, BiondVax will issue 17,000 American Depositary Shares to licensors, with a 1-year lock-up.

Read filing →

June 8, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 ◈ Material Agreements

BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG

Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.
May 4, 2023, 7:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

BiondVax receives Nasdaq deficiency notice for minimum equity; deficit of $1.76M vs $2.5M required

Stockholders' deficit of $1.76M as of Dec 31, 2022, below Nasdaq's $2.5M minimum equity requirement.

Executive changes

Departed

George H. Lowell

Director

SCNI · Scinai Immunotherapeutics Ltd.

Effective: 2023-05-12
Filed: May 11, 2023, 7:59 PM ET

On May 10, 2023, Mr. George H. Lowell submitted to the board of directors (the “Board”) of BiondVax Pharmaceuticals Ltd. (the “Company”) his resignation from his position as a member of the Board, effective May 12, 2023.

Materiality & sentiment trend

Max materiality 0.60 · Median 0.45 · Most common event other_material

0 positive 1 negative 3 neutral

source · SCNI on sec.gov